

Atty. Docket No. PU5020USw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of Duan et al.:

International Application No.: PCT/US03/39732

International Filing Date: December 12, 2003

For: Cyclohexyl Compounds as CCR5 Antagonists

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

Copies of the references are enclosed
 Copies of the references were submitted in parent application Serial No. _____.
(37 CFR 1.98(d))

A copy of the International Search Report which issued on International Application No. PCT/US03/39732 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A. The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

B. The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:
(1) a final action under § 1.113 or
(2) a notice of allowance under § 1.311,
whichever occurs first.

Express Mail Label No.: EV332065709US

Date of Mailing: 6/9/05

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to "Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on the date shown above.

Patty Wilson
Patty Wilson

Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

C. The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. **[or]**


Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and

The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.

Please charge any required fees to Deposit Account No.07-1392.

A duplicate copy of this paper is attached.

Respectfully Submitted,


Bonnie L. Deppenbrock
Attorney of Record
Registration No. 29,208

Date: 9 June 2005

Customer No. 23347

GlaxoSmithKline

Corporate Intellectual Property

5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-1577

Facsimile: (919) 483-7988

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		SERIAL NO. 10/538135
		FILING DATE 10/538135
		APPLICANT Duan et al.
		GROUP
		EXAMINER
		ATTORNEY DOCKET NO. PU5020USw

U.S. PATENT DOCUMENTS

Examiner Initials	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	1. 6,479,487	11/12/2002	Borcherding et al.			

Continue on page

FOREIGN PATENT DOCUMENTS

	Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	2. 1 182 195	2/27/2002	EP			
	3. WO 01/72751	10/4/2001	PCT			
	4. 1 403 25	3/31/2004	EP			
	5. WO 00/49018	8/24/2000	PCT			
	6. WO 97/20823	6/12/1997	PCT			
	7. 44 17 163	11/23/1995	DE			
	8. WO 99/59974	11/25/1999	PCT			
	9. WO 99/64044	12/16/1999	PCT			
	10. WO 97/09308	3/13/1997	PCT			
	11. WO 03/087098	10/23/2003	PCT			
	12. WO 03/069237	8/21/2003	PCT			
	13. WO 03/070244	8/28/2003	PCT			
	14. WO 03/075853	9/18/2003	PCT			
	15. WO 03/028641	4/10/2003	PCT			
	16. 1 378 510	1/7/2004	EP			
	17. WO 01/90106	11/29/2001	PCT			
	18. WO 02/18335	3/7/2002	PCT			
	19. 1 236 726	9/4/2002	EP			
	20. WO 98/25897	6/18/1998	PCT			
	21. WO 01/36418	5/25/2001	PCT			

Continue on page

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

22.	TYLE, Iontophoretic Devices for Drug Delivery, Pharm. Res. 3(6):318-326 (1986).
23.	WOLTERSDORF et al., Topically Active Anhydrase Inhibitors, J. of Medicinal Chemistry, ACS 32(11):2486-2492 (1989).
24.	WITHERINGTON et al., Conformationally restricted indolopiperidine derivates as potent CCR28 receptor antagonists, Bioorg. & Med. Chem Lett. 11(16):2177-2180 (2001).

Continue on page

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.